Skip to content
  • Saturday, 12 September 2026
  • 5:51 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025
Laboratory Automation & Robotics

Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025

Lana Keisha May 4, 2026 0

The Ascent to Pharmaceutical Leadership Eli Lilly’s journey to the top has been nothing short of meteoric. In 2020, the…

Read More
Laboratory Automation & Robotics

Lilly Emerges as Top Pharma Company by Revenue in FY2025, Fueled by Mounjaro and Zepbound’s $36.5 Billion Success

Lana Keisha Apr 26, 2026 0

Eli Lilly and Company has officially concluded its fiscal year 2025 as the world’s leading pharmaceutical enterprise by revenue, a…

Read More
Laboratory Automation & Robotics

Lilly Ascends to Top Pharma Company by Revenue in FY2025, Fueled by Mounjaro and Zepbound’s Explosive Growth

Lana Keisha Apr 19, 2026 0

Eli Lilly and Company has officially claimed the top position in the global pharmaceutical industry by revenue for fiscal year…

Read More
Laboratory Automation & Robotics

Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025

Lana Keisha Apr 11, 2026 0

Eli Lilly and Company has achieved a historic milestone, concluding fiscal year 2025 as the world’s highest-earning pharmaceutical company by…

Read More
Laboratory Automation & Robotics

Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025

Lana Keisha Apr 2, 2026 0

Eli Lilly and Company has officially ascended to the pinnacle of the global pharmaceutical industry, concluding fiscal year 2025 as…

Read More
Laboratory Automation & Robotics

Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025

Lana Keisha Mar 26, 2026 0

Eli Lilly and Company has officially ascended to the pinnacle of the global pharmaceutical industry, achieving the coveted position of…

Read More
UCSF Study Reveals Human Lungs as a Major Source of Blood Cells and Stem CellsNew findings suggest Nereid may not have come into Neptune’s orbit from the Kuiper Belt.Science News: A Century of Empowering Public Understanding of ScienceScientists discover why Ozempic and Wegovy weight loss eventually plateaus
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetLLMOps in 2026: The 10 Tools Every Team Must Have
TWiV 1287: Ancient herpesviruses and modern dementiaJohns Hopkins Researchers Discover How Fusion Genes Drive Rare Kidney Cancer Through Liquid DropletsRNA breakthrough provides hope for thousands of untreatable diseases, including cystic fibrosis, muscular dystrophy and some cancersMerck and Moderna’s cancer vaccine is customized for each patient’s tumor
YOU MAY HAVE MISSED
Microbiology & Immunology
TWiV 1287: Ancient herpesviruses and modern dementia
Lina Irawan Sep 12, 2026
Stem Cell & Regenerative Medicine
Johns Hopkins Researchers Discover How Fusion Genes Drive Rare Kidney Cancer Through Liquid Droplets
Dwi Wanna Sep 12, 2026
Biotech & Genetic Research
RNA breakthrough provides hope for thousands of untreatable diseases, including cystic fibrosis, muscular dystrophy and some cancers
Jia Lissa Sep 12, 2026
Laboratory Automation & Robotics
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
Lana Keisha Sep 12, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ